Please sign in to follow a disease.
Cervical squamous cell carcinoma
MONDO:0006143A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.
Also known as: cervical squamous cell cancer, cervical squamous cell carcinoma, cervix squamous cell carcinoma, cervix uteri squamous cell carcinoma, squamous cell carcinoma of cervix, squamous cell carcinoma of cervix uteri, squamous cell carcinoma of the cervix, squamous cell carcinoma of the cervix uteri
2884 clinical trials for this condition and its sub-types, 36 tagged with Cervical squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Cervical squamous cell carcinoma
-
Cervical adenosquamous carcinoma 16 trials
1 sub-type
-
Cervical basaloid carcinoma 0 trials
-
Cervical verrucous carcinoma 0 trials
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy drug nivolumab tested against tough cervical cancers
Disease control OngoingThis phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a triple therapy beat cervical cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug combo shows promise for Tough-to-Treat gynecologic cancers
Disease control OngoingThis early-phase study tested an oral drug called triapine added to standard chemotherapy (cisplatin) and radiation for people with advanced cervical or vaginal cancer. The main goals were to find the safest dose and check how well the body absorbs the drug. Twenty-one participan…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Vaccine boosts Chemo-Radiation against cervical cancer in early trial
Disease control OngoingThis phase 2 trial tests whether adding a vaccine called PDS0101 to standard chemoradiation is safe and effective for people with advanced cervical cancer. The vaccine trains the immune system to attack HPV-infected tumor cells. About 22 participants will receive the combination,…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental immunotherapy cocktail takes on tough tumors
Disease control OngoingThis early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…
Phase 1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Keytruda takes on 15 advanced cancers in major trial
Disease control OngoingThis phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug cocktail aims to fight cervical cancer without chemo
Disease control OngoingThis Phase 3 trial tests whether a combination of two drugs, camrelizumab and famitinib, works better than standard chemotherapy for women with recurrent or metastatic cervical cancer. About 443 participants will be randomly assigned to receive either the drug combo or chemo. The…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Can yoga ease cervical cancer treatment? small trial aims to find out
Symptom relief OngoingThis study tests whether yoga therapy can improve physical and emotional well-being in people with cervical cancer undergoing chemotherapy and radiation. About 40 participants with stage IB2 to IIIB cervical cancer will attend yoga classes or receive a DVD. The main goal is to se…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Blood test could spot cervical cancer return earlier
Knowledge-focused OngoingThis study looks at whether a blood test can find DNA from the HPV virus that causes cervical cancer. Researchers will collect blood samples from 18 people with cervical cancer before, during, and after treatment. The goal is to see if the test can predict how well treatment work…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC